Evidence map›Paper›PMID 35178209›Full record

ArticleCaspian journal of internal medicine2022

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial.

Mohammadreza Rafati, Hossein Karami, Bita Lashtoo-Aghaee, Bahareh Lashtoo-Aghaee, Mojdeh Dabirian, Razieh Avan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Caspian journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mohammadreza RafatiPharmaceutical Research Center, Department of Clinical Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Hossein KaramiDepartment of Pediatrics, College of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Bita Lashtoo-AghaeeEmam Sajjad Hospital, Ramsar, Iran.
Bahareh Lashtoo-AghaeeDepartment of Microbiology, College of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mojdeh DabirianDepartment of Cardiology, College of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Razieh AvanDepartment of Clinical Pharmacy, Medical Toxicology and Drug Abuse Research Center (MTDRC), Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran.
Birjand University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeta-thalassemia major patients typically require chronic transfusion and iron-chelating agents to reduce serum iron overload. Osveral

methodsIn this randomized clinical trial, all patients received a single daily dose of 30 mg/kg either of Osveral

resultsFinally, 80 patients completed the study. The mean serum ferritin level at the end of sixth month significantly decreased in Osveral

conclusionOsveral

Indexed as

DeferasiroxExjadeFerritinMRI T2*Osveral

Identifiers

PMID35178209
PMCPMC8797811
OpenAlexW4213013251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.